2010
DOI: 10.1016/j.reprotox.2010.05.036
|View full text |Cite
|
Sign up to set email alerts
|

Maternal exposure to mycophenolate mofetil in pregnancy—Results of the ENTIS collaborative study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0
1

Year Published

2010
2010
2012
2012

Publication Types

Select...
3
2

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 0 publications
0
1
0
1
Order By: Relevance
“…As the labeling points out, spontaneous adverse event reporting does not give reliable prevalence rates, because adverse outcomes may be disproportionately reported compared to normal outcomes. An abstract from the European Network of Teratology Information Services reported that malformations occurred in 8 of 50 prospectively ascertained pregnancies after mycophenolate exposure, and that the miscarriage rate (excluding voluntary abortions) was 35% [Hoeltzenbein et al, 2010]. The malformations included microtia, tracheoesophageal fistula, hydronephrosis, and atrial septal defect.…”
Section: Pharmaceutical Productsmentioning
confidence: 99%
“…As the labeling points out, spontaneous adverse event reporting does not give reliable prevalence rates, because adverse outcomes may be disproportionately reported compared to normal outcomes. An abstract from the European Network of Teratology Information Services reported that malformations occurred in 8 of 50 prospectively ascertained pregnancies after mycophenolate exposure, and that the miscarriage rate (excluding voluntary abortions) was 35% [Hoeltzenbein et al, 2010]. The malformations included microtia, tracheoesophageal fistula, hydronephrosis, and atrial septal defect.…”
Section: Pharmaceutical Productsmentioning
confidence: 99%
“…Seltener sind weitere Organsysteme betroffen [99,100]. Erste Ergebnisse einer prospektiven Studie des "European Network of Teratology Information Service" mit 50 Schwangeren ergaben eine Rate für große Fehlbildungen von 21 % und eine Spontanaborthäufigkeit von 35 % [101]. MMF sollte möglichst vor der Schwangerschaft abgesetzt werden.…”
Section: Schwangerschaft Und Stillzeitunclassified